Download
s40265-020-01361-5.pdf 729,85KB
WeightNameValue
1000 Titel
  • Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives
1000 Autor/in
  1. Trojan, Joerg |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-07-15
1000 Erschienen in
1000 Quellenangabe
  • 80(12):1203-1210
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s40265-020-01361-5 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395054/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Relapses are the hallmark of multiple sclerosis (MS). Analyses have shown that the cost of MS increases during periods of relapse. However, results are inconsistent between studies, possibly due to different study designs and the different implications of relapses with respect to patient characteristics.!##!Objectives!#!The aims were to estimate and describe direct and indirect relapse costs and to determine differences in costs with respect to patient characteristics. Furthermore, we describe the pharmacoeconomic impact during the relapse follow-up.!##!Methods!#!Data were extracted from two German, multicenter, observational studies applying a validated resource costs instrument. Relapse costs were calculated as the difference in quarterly costs between propensity score (PS)-matched patients with and without relapses (1:1 ratio). For relapse active patients, we additionally calculated the difference between quarterly costs prior to and during relapse and determined costs in the post-relapse quarter.!##!Results!#!Of 1882 patients, 607 (32%) presented at least one relapse. After PS-matching, 597 relapse active and relapse inactive patients were retained. Relapse costs (in 2019 values) ranged between €791 (age 50 + years) and €1910 (disease duration < 5 years). In mildly disabled and recently diagnosed patients, indirect relapse costs (range €1073-€1207) constantly outweighed direct costs (range €591-€703). The increase from prior quarter to relapse quarter was strongest for inpatient stays (+ 366%, €432; p < 0.001), day admissions (+ 228%, €57; p < 0.001), and absenteeism (127%, €463; p < 0.001). In the post-relapse quarter, direct costs and costs of absenteeism remained elevated for patients with relapse-associated worsening.!##!Conclusion!#!A recent diagnosis and mild disability lead to high relapse costs. The results suggest the necessity to incorporate patient characteristics when assessing relapse costs.
1000 Sacherschließung
lokal Anilides/therapeutic use [MeSH]
lokal Pharmacology/Toxicology
lokal Antineoplastic Agents/adverse effects [MeSH]
lokal Pyridines/therapeutic use [MeSH]
lokal Humans [MeSH]
lokal Pyridines/adverse effects [MeSH]
lokal Review Article
lokal Carcinoma, Hepatocellular/drug therapy [MeSH]
lokal Anilides/adverse effects [MeSH]
lokal Clinical Trials as Topic [MeSH]
lokal Antineoplastic Agents/therapeutic use [MeSH]
lokal Internal Medicine
lokal Liver Neoplasms/drug therapy [MeSH]
lokal Pharmacotherapy
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-9414-378X
1000 Hinweis
  • DeepGreen-ID: 75635bd3527d448e817aa5f9a42862e7 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6465121.rdf
1000 Erstellt am 2023-11-16T10:14:54.012+0100
1000 Erstellt von 322
1000 beschreibt frl:6465121
1000 Zuletzt bearbeitet Fri Dec 01 01:39:04 CET 2023
1000 Objekt bearb. Fri Dec 01 01:39:04 CET 2023
1000 Vgl. frl:6465121
1000 Oai Id
  1. oai:frl.publisso.de:frl:6465121 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source